oneplacenews
Source: Ars Technica
Summary
The FDA has approved a second species of carcass-eating fly for medical use in maggot therapy, expanding options for wound care. This decision is expected to improve treatment outcomes for patients with chronic wounds.
Why It Matters
The approval of a new species for maggot therapy signifies a growing acceptance and innovation in biological treatments for wound care. This can lead to more effective, cost-efficient, and less invasive options for patients suffering from chronic wounds, a significant healthcare challenge.
